Back to results
US 2023/0057461 A1Published application
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
AssigneeThe U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorStavroula Mili
Life of this patent
Estimating the term…
Abstract
Provided herein are antisense oligonucleotides (ASOs) specific for Rab13 and Net1, for example specific for a GA-rich region of the 3′-UTR. In some examples, the ASOs are modified. Methods of using these ASOs to reduce the migration of metastatic cancer cells are provided, for example as a use to treat metastatic cancer.
Claims21
(canceled)
An isolated antisense oligonucleotide (ASO) no more than 28 nucleotides in length, comprising the sequence of any one of SEQ ID NO:
- 8, SEQ ID NO:
- 7, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 30, SEQ ID NO:
- 31 and SEQ ID NO:
- 32, wherein:
- the ASO comprises one or more chemical modifications;
- a detectable label is covalently attached to the ASO;
- and/or
- a nanoparticle is covalently attached to the ASO.
12 more elements
Dependencies are inferred from the claim text.